# Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma

> **NCT05687747** · PHASE1 · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI

## Key facts

- **NCT ID:** NCT05687747
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-18
- **Primary completion:** 2025-08
- **Final completion:** 2026-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05687747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05687747, "Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05687747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*